Objective. A review of the literature was undertaken to evaluate the development and psychometric properties of health-related quality of life (HRQoL) measures used in adults with SLE. This information will help clinicians make an informed choice about the measures most appropriate for research and clinical practice.
Introduction
SLE is a chronic inflammatory autoimmune disorder with variable multi-system involvement that affects primarily young women. The varied manifestations, the unpredictable relapsingremitting course of the disease, side effects of potentially toxic treatments and poor understanding of the condition by the general public all have an impact on patients, leading to dissatisfaction in various domains of their life [1] . Improvement in survival [2] has not reflected a similar improvement in the quality of life [3] for SLE patients. As this condition affects a relatively younger age group, with subsequently longer disease duration, the clinical manifestations may have far-reaching psychological and social consequences [4] . Objective assessments of disease activity and damage are gauged by the clinician and do not capture the patient's perspective of their health [3] . Therefore, more recently it has been emphasized that patient-reported instruments such as those measuring health-related quality of life (HRQoL) should be one of the outcome measures in clinical trials [5] . This has been advocated by both the US Food and Drug Administration (FDA) [6] and the European Medicines Agency (EMA) [7] .
HRQoL measures, in the form of questionnaires, have been either developed exclusively for use in SLE (disease-specific measures) or have been used in SLE patients but developed for evaluation of quality of life in any disease state or healthy individuals (generic measures). An instrument with good psychometric properties will be able to determine the HRQoL of the patient more accurately than one without. Knowledge of acceptable psychometric standards, the conceptual framework and appraisal of the developmental process of HRQoL tools would help determine the adequacy of the measure for clinical use, for example, to determine the effectiveness of an intervention.
The aim of this work was to compare the psychometric properties of all published HRQoL measures (generic and disease specific) that have been developed and/or evaluated for use in adults with SLE. This should provide valuable information to clinicians on the appropriateness of the instrument for measuring HRQoL in their clinical practice as well as in research studies.
Materials and methods

Search strategy
A literature search was carried out using the keywords lupus and quality of life The papers were assessed by all the authors based on the eligibility criteria as defined below:
Inclusion criteria were papers that described the methodology of the development and validation of HRQoL measures in SLE; linguistic translation and evaluation of an existing HRQoL measure and papers that primarily evaluated the measures for SLE patients.
Exclusion criteria were inadequate numbers of SLE patients recruited for the evaluation (Fig. 1) and HRQoL measures published only as abstracts.
Papers that fulfilled any one of the inclusion criteria in the absence of the exclusion criteria were included in this review.
After accounting for duplicates, a total of 374 papers were identified, and after reviewing titles and abstracts, 20 full papers were identified as possibly suitable for this systematic review (Fig. 1) . References of these papers were also screened for additional relevant papers and no further papers were identified. All 20 papers were read by all the authors independently, and using the eligibility criteria, 13 were identified as suitable for inclusion in this systematic review. The reasons for exclusion of the seven papers [814] are explained in Fig. 1 .
Data extraction and quality assessments Data extraction was carried out independently by all the authors. Demographic and clinical data, and information on the description of the instruments and their psychometric properties were extracted. The demographic and clinical data included were age, gender, disease duration, disease activity and damage. Descriptive information of the scales included the number of items, domains, ranges of score, mode of administration, time to administer and recall period. The psychometric properties extracted were validity: content, construct (convergent and divergent), concurrent (criterion) and cross-cultural; reliability: internal and testretest; responsiveness and the floor/ceiling effects. A template was used to assess the psychometric properties of the instrument and the quality of the methodology used to determine that property. The template was based on both the numerical criteria for the qualitative evaluation of an HRQoL instrument proposed by Terwee et al. [15] and the consensus published as the original Consensus Based Standards for the Selection of Health Measurement Instruments (COSMIN) checklist [1619] .
Scoring criteria for evaluation of psychometric properties
The strength of the evidence was rated both for a psychometric property and the robustness of the methodology used to determine that property as follows: (i) strong evidence to support the property and the robustness of the methodology used to evaluate it was schematically rated as three pluses, +++; (ii) moderate evidence was denoted by two pluses, ++; (iii) limited evidence, one plus, +; (iv) no evidence, a minus, À; (v) if interpretation was difficult, a question mark,?; or (vi) not assessed by NA. Any discrepancies in the scores for the measurement properties were discussed by all the authors and agreement was achieved based on the available information.
Psychometric properties
Psychometric properties of a measurement instrument are broadly classified into three domains: validity, reliability and responsiveness. The validity of the instrument includes evaluation of content, construct (convergent/divergent) and criterion validity. Content validity ensures that the measure is sensible, relevant and comprehensively covers all aspects of the condition assessed. In this study, content validity was rated positive if there was involvement of experts (doctors, nurses and social scientists) as well as patients at the stage of questionnaire development. Construct validity evaluates the robustness of the structure and determines the subscales of the questionnaire. Convergent validity was judged to be adequately demonstrated if there was high positive correlations between scales and divergent validity, if correlations were low or if they were negative. Assessment of the instrument against the true value or against a gold standard is termed concurrent (criterion) validity. A positive rating was given if convincing arguments were presented that the comparator questionnaire really was the www.rheumatology.oxfordjournals.org gold standard and the correlation was 50.7. Reliability assesses the reproducibility and consistency of an instrument. Internal reliability or internal consistency measures the extent to which items within a subscale are conceptually related and the acceptable statistical value is Cronbach's a 50.7 [15] . Testretest reliability measures the stability of a questionnaire and is gauged by the intraclass correlation coefficient (ICC). An ICC >0.7 is considered adequate [15] . Responsiveness is the ability of the scale to detect changes within the same patient in longitudinal studies. The instrument was considered to have floor or ceiling effects if >15% of respondents scored at the extreme ends of the scale. The generalizability of the questionnaire was assessed by establishing if the study population was adequately described to help clinicians extrapolate the results to their respective patient cohorts.
Results
Measures included in the review
The measures reviewed can be subdivided into generic or disease-specific HRQoL measures. The generic measures used in SLE were the Medical Outcome Survey Short Form-36 (MOS SF-36 version 1) [2022], Quality of Life Scale, Swedish version (QOLS-S) [23] , Short Form-6D (SF-6D) [24] and EuroQoL-5D (EQ-5D) [24] . These four measures were evaluated in five studies, one for QOLS-S, three on the SF-36 and one study utilizing both the SF-6D and the EuroQoL-5D. The disease-specific measures used in SLE were the Systemic Lupus Erythematosus Symptom Checklist (SSC) [25, 26] , Systemic Lupus Erythematosus-Specific Quality of Life instrument (SLEQOL) [2729] , LupusQoL [30, 31] and L-QoL [32] . The SSC, SLEQOL and LupusQoL have all undergone cross-cultural evaluation [26, 28, 29, 31] .
Description of patients
The demographic data of the patients are tabulated in Table 1 . The gender distribution in the studies reflects the incidence of disease in both genders. Exceptions were the QOLS-S and the developmental phases of both the original LupusQoL [referred to as LupusQoL (UK)] and L-QoL in that only females participated. For the instruments developed in Europe, the age distribution, disease duration and disease activity of the samples were similar. The studies within the Chinese population included younger patients with less disease activity and damage and shorter disease duration. For ethnicity distribution, some authors [22, 24, 32] did not mention the ethnic profile of the samples.
Description of the questionnaires
This is summarized in supplementary Table S1 , available as supplementary data at Rheumatology Online. All measures except the SSC and L-QOL have multiple domains. All the questionnaires were developed in English-speaking populations except the QOLS-S (Swedish) and the SSC (Dutch). Cross-cultural validation was undertaken for the SF-36 (to Chinese), SSC (to Brazilian Portuguese), SLEQOL (to Brazilian Portuguese) and LupusQoL (UK) (to US English).
The number of items/response options, scoring range/ interpretation, time for administration and recall time for each measure are also summarized in supplementary  Table S1 , available as supplementary data at Rheumatology Online. The response options varied in the different measures with most questionnaires using a 5-point or 7-point Likert scale [33] . For the SF-36, SF-6D, QOLS-S, EQ-5D and LupusQoL, higher scores reflected better health, while for SLEQOL, SSC and L-QOL the reverse was true. The time for administration of the questionnaires, when stated, was <10 min for all measures. The measures had varying numbers of items (540) and recall periods (present time to the previous 4 weeks and up to the previous year for the general health item in the SF-36) with the most typical recall period being the previous 4 weeks.
Psychometric properties of the questionnaire
The psychometric properties tabulated in Tables 2 and 3 include validity (content, criterion and construct), reliability (internal consistency and testretest reliability) and responsiveness. These properties are further described/ analysed in the following paragraphs.
Content validity
Qualitative interviews or other ways of involving patients and experts (rheumatologists and nurse clinicians) were an essential part of the development of the disease-specific measures and the QOLS-S. In the case of generic measures, the content validity was assumed for an SLE population.
Construct validity
The construct validity was evaluated using different methods and statistical analyses in the different papers. Factor analysis carried out for the SF-36 failed to sufficiently support the proposed domains in the studies [21, 22] . QOLS-S used the consensus model, whereas SF-6D and EQ-5D had no factor analysis done. In comparison, the factor analyses for all of the disease-specific measures except the SLEQOL confirmed the dimensionality and the domain structure. The developers of SLEQOL based the final subsections on convenience.
Correlation coefficients were used to determine convergent and divergent validity to test a priori hypotheses. Convergent validity was evaluated against different measures in the various studies. This was not assessed adequately for the SF-36, SF-6D and EQ-5D. The QOLS-S was compared against the Arthritis Impact Measurement Scale, with moderate correlation between the psychological score and the QOLS-S for SLE patients. All the disease-specific measures used the SF-36 as a comparator measure for convergent validity, except the L-QoL, which used the Nottingham Health Profile (NHP). The LupusQoL (US) used the EQ-5D in addition to the SF-36. Moderate to strong correlations were noted for www.rheumatology.oxfordjournals.org the disease-specific measures except for the SLEQOL. The evaluation of divergent validity and discriminant validity was against the disease activity measures (the BILAG index or the SLEDAI) and the damage index [SLICC/ACR Damage Index (SLICC/ACR-DI)] for all studies. Weak or no correlations supported the divergent validity of both generic and disease-specific measures. The diseasespecific measures had moderate evidence for construct validity, but the generic measures had limited evidence for this.
Concurrent (criterion) validity
The SF-36, SF-6D and LupusQoL (US) were derived from the SF-20, SF-36 and LupusQoL (UK), and therefore had gold standards for determining the concurrent criterion validity. The SF-36 and SF-6D showed strong correlation coefficients in most domains when compared with the original instrument. Concurrent validity was not reported in the LupusQoL (US), and thus this property could not be adequately explored for this instrument.
Internal consistency
There was moderate to strong evidence for internal consistency in all the measures except the SF-6D and EQ-5D. The scoring was evaluated as moderate due to the smaller sample sizes in the studies for the Chinese SF-36 and the QOLS-S. For all the scales, the mean internal consistency (Cronbach's a) was >0.80. All of the disease-specific measures had high mean ICC, although the individual domains ranged from 0.57 to 0.93 across measures.
Testretest reliability
Testretest reliability varied for the different domains in the various measures. Four of the measures [Chinese SF-36, SSC, QOLS-S and LupusQoL (US)] used sample sizes of fewer than 50, which is the minimum number recommended for such analyses [15] . For all the instruments the mean ICC was >0.70. The English and the Chinese versions of the SF-36 assessed in the Singapore population employed the Bland and Altman repeatability coefficient. Two of the domains were found to have large changes, thus bringing into question the reliability of these domains. The SLEQOL had good ICC for the overall score on testretest reliability, but the scores of the subsections were below the accepted 0.70 in four of the six domains. The LupusQoL (UK) had strong evidence for good methodology and ICC, but only two of the eight domains had a sample size of more than 50 patients. From the data available it is clear that the generic measures have limited evidence for testretest reliability, whereas the disease-specific measures appear to fare marginally better with limited to moderate evidence for this property.
Responsiveness and floor/ceiling effect Percentages of floor and ceiling effect were provided for the EQ-5D, SF-6D, SLEQOL, SF-36 (Singapore) and LupusQoL (UK). The EQ-5D and SF-6D did not show either effect, the SLEQOL reported floor effects and the SF-36 (Singapore) and LupusQoL (UK) were noted to have ceiling effects in some of the domains. The responsiveness or sensitivity to change was assessed in four of the HRQoL measures (SLEQOL, SSC, EQ-5D and SF-6D).
Although the SSC scores improved statistically, the patients (on treatment with cyclophosphamide) did not perceive any change as per the patient's visual analogue scale (VAS). The authors attributed this to the psychological adaptation in patients with chronic illness and to the small sample size. For the EQ-5D and SF-6D, only small effect sizes were demonstrated. Table 4 summarizes schematically the level of evidence for the main psychometric properties of the HRQoL measures that have been evaluated in this review. There is strong to moderate evidence for good reliability, internal consistency and validity for the disease-specific measures. The internal consistency was strong to moderate for both generic and disease-specific measures.
Generalizability
The description of the study sample was available in all the measures except QOLS-S, SSC and L-QOL. This important omission makes it difficult for the reader to determine the population for which the measure is best suited.
Discussion
This review highlights some deficiencies in the HRQoL measures used in SLE patients. Comparison of the studies was difficult due to the varied methodology employed by the different authors. This is partly because the studies were undertaken at different time periods (between 1997 and 2010) and reflected the trend in the development of quality of life measures over the years. Despite this, all the HRQoL measures developed/evaluated for use in SLE patients have moderate to strong evidence for content validity and internal consistency. The structure of a good measure should emphasize and evaluate the domains of importance to the patients. All the disease-specific measures have addressed this adequately. However, there was limited evidence for construct validity for the generic measures.
Only a stable measure can be used with confidence in clinical studies. Accuracy in determining the changes of HRQoL in a clinical situation is crucial if the measure has to evaluate any improvement, deterioration or lack of change in the patients' quality of life. Only some of the disease-specific measures have moderate evidence for testretest reliability and this was not demonstrated adequately in the generic measures.
In addition, responsiveness and floor and ceiling effects were not evaluated in all measures. In those measures where they were evaluated, there was limited evidence for responsiveness of the SLEQOL, EQ-5D and SF-6D, while the evidence for the SSC was inconclusive. For a clinician to be able to benefit from using an HRQoL measure it is essential that responsiveness is evaluated, so that data from interventional studies can be interpreted more accurately.
The settings in which the surveys were administered (outpatient clinics, inpatient, postal surveys or a mixture of these) may have introduced bias. Although this makes it difficult to compare, it would reflect the bias in subsequent administration of the measures in similar settings.
Appropriate samples are important in terms of both composition and size. Sample size calculations and the reasoning behind the numbers recruited would have added to the robustness of the studies. Acknowledging missing data in any study is also important, as it not only highlights the possible areas of difficulties for the subjects, but also gives the researchers the opportunity to scrutinize any deficiencies of the questionnaire. Missing data were described in all the studies, but how they subsequently affected the developmental process of each questionnaire was not described in any of the papers.
The selection of the most appropriate instrument to use in a study will be determined by the aims of that study. A unidimensional measure lends itself more to economic evaluation. On the other hand, a multidimensional measure addresses the various aspects vital to the concept of quality of life to an individual. Multidimensional measures help to identify areas that need to be targeted for intervention to improve the quality of life for an adult with SLE.
Guidelines from the FDA and EMA encourage the use of patient-reported outcome evaluations in studies on the development of interventions, especially new medications. The validation of HRQoL instruments is essential to ascertain that these tools are robust and can thus be confidently used by clinicians. In this review, it is evident that the methodologies employed in the process of HRQoL development have not been uniform across the measures. The recently published COSMIN checklist [1619] , developed by international consensus, will hopefully inform future research and lead to a more uniform approach that would aid comparison. However, all the measures that have been discussed in this review were developed prior to the publication of this guidance.
In conclusion, based on the published studies reviewed, the disease-specific multidimensional measures have the strongest evidence for content and construct validity as well as internal consistency. More studies would be required to support the stability of these measures and their sensitivity/responsiveness. If these properties are supported, it would then make the disease-specific measures strong contenders for use in clinical practice and interventional studies in adult SLE populations.
Rheumatology key messages
. Stronger evidence exists for reliability and validity of SLE disease-specific HRQoL measures than for generic measures. . HRQoL measures used in SLE should be evaluated for responsiveness to aid clinical interpretation.
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